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Thrombostatic Agents and Tissue 
Adhesives in the Emergency 
Department: Stopping the 
Bleeding, Closing the Wound, and 
Novel Applications
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and Rebecca Jeanmonod
Abstract
Complaints of bleeding are frequent presentations to the emergency depart-
ment, and although most bleeding can be controlled with direct pressure, increased 
use of antiplatelet agents and anticoagulants complicates what might be otherwise 
simple bleeding. Industry has met the demand for hemostatic adjuncts, and a 
number of products are available for the emergency physician to assist in hemostatic 
control and wound closure. This chapter will cover the various available technolo-
gies, covering their preferred use and discussing particular bleeding scenarios and 
which technology may be best for each scenario.
Keywords: topical hemostatic agent, tissue adhesive, bleeding scenarios
1. Introduction
Control of bleeding wounds has always been a priority in managing injured 
patients, and providers have used numerous adjuncts to staunch bleeding for 
decades, with variable success. The earliest use of topical hemostatic agents dates 
from the end of the nineteenth century when thrombin was used by boxers and 
barbers to control bleeding from lacerations [1]. Almost a century before the clot-
ting cascade was completely elucidated, in 1909 Bergel had described using topical 
fibrin to stop surgical bleeding [2–4]. Subsequently, surgeons utilized fibrinogen 
in plasma as well as bovine thrombin to assist in a variety of surgical scenarios, 
including nerve repair and skin grafting [5, 6]. Commercial products first became 
available in Europe in 1972, but the Food and Drug Administration did not 
approve fibrin sealants in the United States until 1998 [3]. Over the course of time, 
numerous other types of hemostatic agents have been developed, each unique in 
their load bearing capacity, biomechanical properties, handling, derivation, and 
application [7].
Cutaneous and mucous membrane bleeding are common presentations to 
emergency departments. Data from the National Hospital Ambulatory Medical 
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Care Survey in 2002 estimated that there were 7.27 million emergency department 
visits for lacerations, representing approximately 6.6% of all emergency depart-
ment visits [8], and data from HCUP National Emergency Department Survey in 
2013 estimated about 7 million emergency department visits or 5.2% of all visits for 
lacerations [9]. There are no data to quantify how many of these visits are associated 
with uncontrolled or major bleeding. The mainstays of treating bleeding remain 
the simple application of direct pressure with a pressure bandage and application 
of tourniquet if hemostasis is unable to be obtained. However, there are times that 
application of hemostatic agents can assist in bleeding control. In the modern era, 
with widespread use of anticoagulant and antiplatelet agents, as well as physiologi-
cally induced coagulopathies from liver disease and uremia, development of topical 
hemostatic agents to assist in terminating complex bleeding scenarios has become 
important.
We will briefly review classes of tissue adhesives, topical hemostatic agents, and 
the best practice data regarding each in the setting of the emergency department. 
We will provide common clinical bleeding scenarios and the application of these 
materials in those situations.
2. Topical hemostatic agents
Topical hemostatic agents generally fall into one of two categories: the physical 
agents that work by providing a physical substrate which promotes hemostasis and 
the biologically active agents that enhance coagulation at the site of action(Table 1). 
In the emergency department, topical hemostatic agents are primarily used as 
adjuvant therapy to direct pressure to stop persistent bleeding from lacerations and 
abrasions that are not amenable to suture control, such as distal fingertip avulsions, 
flap lacerations with avulsion of the flap, and skin tears in the elderly. As well, 
topical hemostatic agents can be used to assist with persistent bleeding from nasal 
mucosa, gingival tissue after tooth extraction, and from vascular bleeding sites such 
as persistently bleeding dialysis access sites or bleeding lower extremity varices.
Little data exists to suggest superiority of a single agent over others, and often 
selection of an agent is based on availability, familiarity with its use, patient and 
wound characteristics, and cost.
2.1 Physical matrix topical hemostatic agents
2.1.1  Gelatin matrix (Gelfoam® [Pfizer Inc., New York, NY, USA], Surgifoam® 
[Ethicon Inc., Somerville, NJ, USA], Floseal® [Baxter International, 
Deerfield, IL, USA])
Gelfoam® and Surgifoam® are porcine derived, non-soluble, gelatin matrices 
that are in a compressed sponge form [10, 11]. They can be cut to appropriate size 
for application and when applied to bleeding sites are able to absorb 45 times their 
weight in whole blood. Floseal® is a combination of bovine-derived, liquid gelatin 
matrix and human-derived thrombin that is supplied in a syringe with an applicator 
tip that assists with mixing the components and application at the site of bleeding 
[12]. The mechanism of action of gelatin matrix is poorly understood but is thought 
to be due to its physical properties, providing a structural support for clot forma-
tion rather than a direct effect on the clotting cascade. In clinical use, these agents 
are appropriate for topical application to persistently bleeding sites, such as dental 
extraction sites, in the management of epistaxis, and in fingertip avulsion inju-
ries. These agents typically have minimal tissue reaction and are absorbed within 
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6 weeks when placed within soft tissues or liquified and absorbed within 2–5 days 
when applied to bleeding mucosal sites.
Little data exists studying the efficacy of gelatin matrices for bleeding compli-
cations in the emergency department setting. In a small prospective, randomized 
study of patients who failed anterior packing for epistaxis, Floseal® application 
demonstrated equal rates of hemostatic control as repeat anterior packing by 
a specialist, and lower, but not statistically significant, rates of hospitalization 
[13]. A larger, prospective randomized sample of patients with epistaxis managed 
initially with Floseal® versus anterior packing demonstrated that Floseal® was 
associated with improved patient satisfaction and less rebleeding [14]. In a small 
convenience sample of patients presenting with posterior epistaxis, Floseal® was 
successfully used to control bleeding in 80% of patients at a significantly reduced 
cost when compared to surgery, posterior packing with hospital admission, and 
embolization [15].
Complications from gelatin matrix applications are reported to be minimal but 
include the potential to form a nidus for infection or abscess formation, foreign 
Product Manufacturer
Physical matrix topical hemostatic agents
Gelatin matrix Gelfoam® Pfizer Inc., New York, NY, USA
Surgifoam® Ethicon Inc., Somerville, NJ, USA
Floseal® Baxter International, Deerfield, IL, 
USA
Oxidized regenerated cellulose Surgicel® Ethicon Inc., Somerville, NJ, USA
SafeGauze® Medicom, Montreal, QC, Canada
Microporous polysaccharide 
spheres
Arista® AH CR Bard Inc., Murray Hill, NJ, USA
Microfibrillar collagen Avitene® CR Bard Inc., Murray Hill, NJ, USA
Chitosan HemCon® Tricol Biomedical Inc., Portland, 
OR, USA
Chitoflex® Tricol Biomedical Inc., Portland, 
OR, USA
TraumaStat® Ore-Medix, LLC Company, 
Lebanon, OR, USA
Celox® Medtrade Products LLC., Crewe, UK
ChitoSAM® Sam Medical, Tualatin, OR, USA
Axiostat® Axio Biosolutions PVT LTD. Gujarat, 
India
Biologically active topical hemostatic agents
Topical thrombin Thrombin JMI® Pfizer Inc., New York, NY, USA
Tranexamic acid (TXA) Multiple generics
Cyklokapron® 100 mg/ml Pfizer Inc., New York, NY, USA
Erfa Tranexamic® 
100 mg/ml
Erfa Canada 2012, Inc., Montreal, 
QC, Canada
Kaolin QuickClot® Z-Medica LLC., Wallingford, CT, 
USA
Table 1. 
Topical hemostatic agents.
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body reactions with encapsulation of reactive fluid, and toxic shock when used in 
nasal application.
2.1.2  Oxidized regenerated cellulose (Surgicel® [Ethicon Inc., Somerville, NJ, 
USA], SafeGauze® [Medicom, Montreal, QC, Canada])
Surgicel® is a sterile, knitted, absorbable fabric produced from plant cellulose. 
The mechanism of action of Surgicel® is poorly understood, but is thought to 
produce a mechanical scaffolding for clot formation rather than have a direct effect 
on the clotting cascade [16]. In clinical use, these agents are appropriate for topical 
application to persistently bleeding sites, such as dental extraction sites and in the 
management of epistaxis. As opposed to the gelatin matrices, which can be used 
wet or dried, the efficacy of Surgicel® is superior if it is applied dry to the area of 
bleeding, so it may not be appropriate for use with topical thrombin. As Surgicel® 
undergoes reaction with the tissue, it produces an acidic environment, which has 
been demonstrated to have in vivo bactericidal properties. The acidic environment 
that it produces may impair wound healing, perhaps making it a less optimal choice 
for controlling bleeding in large areas of tissue avulsion. Complications of its use 
have primarily reported to be localized tissue reactions.
2.1.3  Microporous polysaccharide spheres (Arista® AH [CR Bard Inc., Murray 
Hill, NJ, USA])
Arista® AH is a powder hemostatic agent derived from plant polysaccharides. 
The mechanism of action of Arista® is poorly understood, but is thought to produce 
a mechanical scaffolding for clot formation rather than have a direct effect on the 
clotting cascade [17]. Its powdered form has limited use in an emergency depart-
ment environment.
2.1.4 Microfibrillar collagen (Avitene® [CR Bard Inc., Murray Hill, NJ, USA])
Avitene® is a microfibrillar collagen hemostat available as a sponge, sheet, and 
powder. The collagen matrix of Avitene® is thought to promote platelet activa-
tion, inducing clot formation [18]. Avitene® has been on the market for more than 
40 years and has widespread applications in surgical hemostasis and epistaxis 
treatment.
2.1.5  Chitosan (HemCon® [Tricol Biomedical Inc., Portland, OR, USA], 
Chitoflex® [Tricol Biomedical Inc., Portland, OR, USA], TraumaStat® 
[Ore-Medix, LLC Company, Lebanon, OR, USA], Celox® [Medtrade 
Products LLC., Crewe, UK], ChitoSAM® [Sam Medical, Tualatin, OR, 
USA], Axiostat [Axio Biosolutions PVT LTD. Gujarat, India])
Chitosan is a naturally occurring polycationic polysaccharide derived from 
multiple sources including shrimp, crabs, and certain fungi. The hemostatic 
mechanism of chitosan is incompletely understood, but is thought to include 
gelatinous aggregation of red blood cells, platelet activation, and contact system 
activation [19].
In a case series of 35 patients on antiplatelet agents or anticoagulants who failed 
initial management with cautery and nasal packing, 32 patients were successfully 
treated with application of a foam anterior pack wrapped in a chitosan sheet [20]. 
A small study of 40 patients on oral anticoagulation undergoing multiple tooth 
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extractions compared a site treated with a chitosan pledget with a site treated with 
gauze and pressure and found decreased bleeding times and decreased postopera-
tive pain in the chitosan treated site [21]. Another small study of 20 patients on 
oral anticoagulants undergoing dental extraction of multiple teeth found that 
the extraction sites treated with chitosan had shorter bleeding times than control 
extraction sites treated with a collagen matrix plug [22].
2.2 Biologically active topical hemostatic agents
2.2.1 Topical thrombin (Thrombin JMI® [Pfizer Inc., New York, NY, USA])
Thrombin is a protein which is part of the clotting cascade and has the effect 
of activating fibrinogen to fibrin, which is essential for clot formation, as well as 
activating platelets. Several formulations exist on the market, and thrombin can be 
of bovine or human origin. Topical thrombin can be applied to mucosal bleeding 
sites such as dental sites and epistaxis or can be applied topically. Additionally, topi-
cal thrombin can be used in conjunction with gelatin matrix sponges. No clinical 
trials comparing efficacy to other techniques have been published. Because these 
products are derived from other species or individuals, the primary complications 
include sensitivity reactions or rarely antibody formation against factor V, resulting 
in life-threatening bleeding complications [23].
2.2.2  Tranexamic acid (TXA) (multiple generics, Cyklokapron® 100 mg/ml 
[Pfizer Inc., New York, NY, USA], Erfa Tranexamic® 100 mg/ml [Erfa 
Canada 2012, Inc., Montreal, QC, Canada])
Tranexamic acid is a synthetic derivative of the amino acid lysine that inhibits 
fibrinolysis by reversibly blocking the interaction of plasminogen with the lysine 
fragments on fibrin. The intravenous formulation of TXA is typically 100 mg/ml, 
which is equivalent to a 10% solution. Intravenous TXA formulations can be used 
topically as adjuvant treatment for patients with epistaxis, oral bleeding, or bleed-
ing from topical sites.
A randomized controlled trial of 216 patients who were randomized to receive 
an anterior nasal packing soaked in 5 ml of 10% solution versus lidocaine plus epi-
nephrine found that those treated with TXA had more rapid resolution of bleeding 
and earlier emergency department discharge [24]. A study of 124 patients taking 
antiplatelet agents who were randomized to TXA versus anterior packing also found 
more rapid resolution of bleeding as well as decreased visits for rebleeding [25]. A 
retrospective analysis of oral bleeding in 542 patients demonstrated improvement 
in bleeding in patients treated with TXA-soaked gauze and compression over use 
of gauze alone [26]. A systematic review of 5 studies including 252 patients taking 
oral anticoagulants undergoing dental procedures found that TXA was significantly 
protective against bleeding with a RR of 0.13 (95% CI 0.05–0.36; p < 0.0001) [27]. 
In addition to using the intravenous formulation of TXA topically, a paste of TXA 
can be made by crushing several 650 mg TXA tablets and adding small aliquots of 
saline to form the paste.
2.2.3 Kaolin (QuickClot® [Z-Medica LLC., Wallingford, CT, USA])
Kaolin is an inorganic mineral that has been demonstrated to promote activation 
of Factor XII, which is the first step in the activation of the intrinsic pathway of the 
clotting cascade. Kaolin-impregnated gauze is primary developed for controlling 
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hemorrhage from external wounds in non-compressible sites in the setting of 
military and civilian trauma.
Little data exists evaluating the effectiveness of kaolin gauze in humans. In 
swine models of uncontrolled hemorrhage, QuickClot® outperformed comparative 
hemostatic agents in terms of survival [28].
Although the manufacturer states that there are no complications with the use 
of QuickClot® because it is not biologically derived, there is a case report of thermal 
burn with its use [29].
3. Tissue adhesives for wound closure
When it comes to primary wound closure, skin adhesives have several advan-
tages over traditional suture repair. They bond quickly, resulting in saved time on 
the part of the physician performing the repair, and they are less painful than stan-
dard suture repair [30, 31]. They do not require a second visit for suture removal, 
saving the patient time and reducing the burden to the health-care system [30]. The 
closure is strong, similar in strength to healed tissue at 7 days post-repair [30]. In 
addition, the closure with tissue adhesives is cosmetically similar to that achieved 
with standard suture closure [31]. Tissue adhesives are more expensive than suture 
materials, but that cost is offset by the inherent costs associated with physician time 
to suture, bandaging, and repeat visit for suture removal [32]. In a busy and unpre-
dictable emergency department, this time saving is essential.
Unlike topical hemostatic agents, which are often natural polymers, tissue adhe-
sives used for wound closure in the emergency department are primarily synthetic 
polymers [33]. This is largely due to their high tensile strength, flexibility, and 
ability to form mechanical bonds [33]. The three primary classes of tissue adhesives 
used for wound closure are polyurethane-based tissue adhesives, polyethylene 
glycol-based tissue adhesives, and cyanoacrylate synthetic glues [33].
3.1 Polyurethane-based tissue adhesives
Polyurethane-based tissue adhesives are not commonly used in emergency prac-
tice, although they do have applications in surgical practice. The isocyanate pre-
polymers in the adhesive bond to the amines in tissue proteins, forming a urea bond 
[3]. Historically, there have been issues with polyurethane-based tissue adhesive 
toxicity (including thrombosis and hemolysis) and long setup time [3], but they are 
undergoing development currently using various concentrations of castor oil and 
other additives to optimize their surgical adhesive properties [34, 35]. Although 
there is currently some application of these adhesives in the operating theater in 
renal, plastics, and orthopedic surgery, they are not currently used for traumatic 
injuries typically seen in the emergency department. As they have shown promise 
in reducing seroma formation in surgical wounds, they may have applications for 
larger traumatic wounds in the future.
3.2 Polyethylene-based tissue adhesives
Polyethylene-based adhesives are not currently typically used in emergency 
practice. Like polyurethane-based adhesives, they are primarily used inside the 
body, with current uses most commonly related to sealing lung surgical sites and 
preventing dural leaks after neurosurgery [36]. These adhesives have a very fast 
setup time and are strong and biodegradable [36]. They have potential for emer-
gency department application in the future.
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3.3  Cyanoacrylate synthetic glues (Dermabond® [Ethicon Inc., Somerville, NJ, 
USA], Histoacryl® [BBraun, Melsungen, Germany], SurgiSeal® [Adhezion 
Biomedical LLC., Reading, PA, USA], Periacryl® [GluStitch, Delta, BC, 
Canada], Glu-Stitch® [GluStitch, Delta, BC, Canada], Indermil® [Surgical 
Specialties, Frenchs Forest, NSW, Australia])
Cyanoacrylate synthetic glues are by far the most common tissue adhesives used 
for wound repair in emergency departments (Table 2). These glues were initially 
developed during attempts to make a clear plastic. Initially, they were too brittle and 
caused significant inflammation to tissue but subsequently underwent tremendous 
redesign over the course of decades prior to their final approval by the FDA in the 
form of 2-octyl cyanoacrylate in the late 1990s [3, 30]. Cyanoacrylate glues are mono-
mers that react upon contact with water on tissue in an exothermic reaction, causing 
them to polymerize across the wound edges, allowing healing to take place below. 
These agents are also antimicrobial, which is an additional advantage [3, 30, 32].
Cyanoacrylate glues have the tensile strength of 5-0 suture, and they reach their 
maximal bonding strength 2.5 min after application [30]. Given these properties, 
it stands to reason that wounds most appropriate for glue repair are wounds that 
would require a suture strength of 5-0 or 6-0. Therefore, cyanoacrylate synthetic 
glues are not recommended for wounds under tension such as those crossing joint 
lines, highly gaping wounds, or wounds in very moist areas of the body [30, 32]. 
It is acceptable to use tissue adhesive glue on wounds that require deep sutures to 
reduce tension and gaping on the wound, so long as after those sutures are placed, 
the wound would be appropriate for closure with 5-0 or 6-0 suture. Cosmetically, 
cyanoacrylate has similar outcomes to standard sutures in appropriately chosen 
lacerations but a slightly higher risk of dehiscence [30, 31].
Tissue adhesive should be applied to an appropriately cleaned and dry wound. 
The wound edges should be approximated, and the adhesive should be applied over 
the approximated edges three to four times [30]. The hydroxyl ions in the wound 
edges activate the adhesive and seal the wound. The adhesive should never be intro-
duced into the wound. In addition to causing an exothermic reaction because of the 
amount of moisture, it creates a foreign body reaction, with tissue inflammation 
and poor healing [30, 32]. Tissue adhesives should therefore not be used on heavily 
contaminated wounds, bites, macerated wounds, or wounds that are complex and 
difficult to approximate [30–32].
3.3.1 Novel uses for cyanoacrylate tissue glue
Cyanoacrylate glues are used in oral surgery practice, but their use for dental 
injuries in the emergency department is currently off-label. Nevertheless, tissue 
Product Manufacturer
Cyanoacrylate synthetic glues Dermabond® Ethicon Inc., Somerville, NJ, USA
Histoacryl® BBraun, Melsungen, Germany
SurgiSeal® Adhezion Biomedical LLC., Reading, PA, USA
Periacryl® GluStitch, Delta, BC, Canada
Glu-Stitch® GluStitch, Delta, BC, Canada
Indermil® Surgical Specialties, Frenchs Forest, NSW, Australia
Table 2. 
Tissue adhesives.
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adhesives have found a niche in emergency department management of dental 
injuries. In the setting of an acutely fractured tooth involving exposed dentin 
(which is extremely painful), standard of care is to cover the exposed fracture site 
with calcium hydroxide paste. If this is unavailable, some providers advocate for 
using cyanoacrylate glue to cover the exposed dentin, as it controls pain and can be 
removed without difficulty using a solvent in the dentist’s office [37, 38]. One study 
also evaluated the use of cyanoacrylate for pain control in carious teeth, which 
found it effective for pain control [38]. Cyanoacrylate has antimicrobial properties, 
which provides theoretical benefits in these settings. However, cyanoacrylate has 
not been studied for safety in these scenarios, nor has it been assessed for adverse 
events, only for pain control. Therefore, the physician needs to be aware that any 
use of cyanoacrylate in treatment of dental fractures in the emergency department 
setting is not evidence-based.
In patients with avulsed and replanted teeth or in those with subluxed teeth, 
cyanoacrylate can be useful in splinting the injured tooth.
4. Adverse effects and complications of topical hemostatic agents
Topical hemostatic agents, tissue adhesives, and sealants may have adverse 
effects usually related to the composition of the agent, location of placement of 
the agent, and the absorption times of the agent. Slowly degrading products can 
serve as a nidus for infection especially if excessive amounts are used. In many 
cases, these agents are used in confined places and can then lead to compression 
of surrounding structures. Many of the complications associated with these 
agents are related to surgical uses rather than emergency department applica-
tions [39].
4.1 Air embolism
Air embolism is a rare complication that has been reported with the use of 
injectable agents such as spray thrombin or fibrin sealant. Care must be taken when 
spraying these objects so as not to exceed recommended pressures and to spray at 
an appropriate distance from the affected tissue. There are no reported cases of air 
embolism secondary to use of an atomizer, as may be used with TXA [40–42].
4.2 Wound infection
Wound infection may be associated with the use of topical hemostatic agents. 
It is difficult to analyze the risk of infection due solely to hemostatic agents versus 
due to confounding factors. Adverse factors, such as type and location of wound, 
foreign body material in the wound, and etiology of the wound, all play a role in 
development of wound infection. If a patient has other systemic symptoms that 
need to be addressed and needs urgent or emergent wound closure, that too can 
play a role in development of wound infection. The risk of infection, as it relates 
to hemostatic agents, can be minimized by cleaning the wound thoroughly and 
removing excess topical agent after hemostasis is achieved.
4.3 Impaired wound healing
Impaired wound healing may be due to failure to effectively close the wound, 
dehiscence of the wound repair, and excessive amounts of hemostatic agent 
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being used. When excessive amount of agent is used, as in cyanoacrylate closure, 
increased metabolites can form and cause an inflammatory response in the sur-
rounding tissue which leads to poor wound healing [43].
4.4 Hypotension
Hypotension has been reported in some individuals receiving injections of 
bovine-derived products, such as thrombin. The hypotension is believed to occur 
with higher than normal concentrations of bovine thrombin but has been noted 
to be mostly transient lasting less than a minute. The hypotension does respond 
to epinephrine, if needed, and can be avoided by reducing the amount of bovine 
thrombin used and compression of injection sites [44–46].
4.5 Allergic reactions and anaphylaxis
Anaphylaxis and allergic reactions are also mostly related to bovine-derived 
products. These products must be avoided in individuals with a history of prior 
anaphylactic reactions to plasma products or IgA deficiency [47].
4.6 Infectious disease transmission
Infectious disease transmission is a potential complication when any products 
using blood components are used, and transmission may be more likely when 
hemostatic agents are used in an aerosolized form. Though there is a theoretical risk 
of viral transmission, including HIV and hepatitis, with topical hemostatic agents, 
there have been no reported cases in the last 20 years [48].
4.7 Vascular thrombosis
Vascular thrombosis is also a theoretical risk; however, there is no increased rate 
of vascular or graft thrombosis with the use of topical hemostatic agents. Great 
care must be taken not to inject these agents into a blood vessel or opened vessel 
[49, 50].
4.8 Immune-mediated bleeding
An immune-mediated bleeding diathesis can occur with the use of bovine 
thrombin preparations. The diathesis occurs due to development of a factor V 
deficiency secondary to an antibovine factor V antibody that cross-reacts with 
endogenous factor V. The risk of this complication can be reduced by using human 
thrombin. If patients have prior exposure to a bovine thrombin, antibodies may 
persist for years, and if known bovine thrombin should be avoided [51, 52].
5. Bleeding scenarios
Much of the literature found on uses of topical hemostatic agents for bleed-
ing involves surgical and perioperative indications. However, different bleeding 
scenarios may present to the emergency department where topical adhesives and 
hemostatic agents may be of benefit. We will discuss some of these indications, 
including cutaneous bleeding, varicosity bleeding, AV fistula bleeding, post-tooth 
extraction bleeding, and epistaxis.
Biosurgicals - The Next Frontier in Operative Approaches
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5.1 Bleeding wounds
Approximately 6 million minor wounds are treated in emergency departments 
in the United States every year. Most cutaneous bleeding occurs due to lacerations 
of the skin. These lacerations can be caused by blunt or penetrating trauma to the 
epidermal and dermal layers. Management of these minor wounds has three goals: 
control of bleeding, avoidance of infection, and cosmetically acceptable, functional 
scars. Many factors contribute to management of these wounds. The wound must 
be assessed, and factors such as age of injury, mechanism of injury, extent of 
wound, neurovascular injury, and location of wound all play a role in determining 
the type of closure employed. Hemostasis of these wounds must be accomplished, 
and most times simple pressure for 10–15 min can achieve this. Persistent bleeding 
may require lidocaine with epinephrine injected or applied to the wound. In those 
cases where bleeding is difficult to stop, the direct application of surgical absorb-
able gelatin foam (Gelfoam®) to the wound is an alternative method of achieving 
hemostasis. Gelfoam®, however, should not be used in infected wounds or at the 
skin closure site because it may delay healing. After achieving hemostasis, wounds 
may require debridement, irrigation, and foreign body removal. Once the wound 
has been adequately assessed and prepared, primary closure with suture, staples, 
skin tape, or topical adhesive may be utilized. The most common topical adhesives 
used in the emergency department are cyanoacrylate synthetic glues. These offer 
tensile strength equivalent to 5-0 sutures. They have similar cosmetic outcomes to 
sutures but do have a slightly higher risk of dehiscence [53–55].
5.2 Bleeding varicosities
Varicose veins are dilated, elongated, tortuous, subcutaneous veins 3 mm or 
greater in diameter. They may involve the saphenous veins, saphenous tributaries, 
or superficial leg veins. Complications of varicose veins most commonly include 
superficial vein thrombosis and bleeding and, though uncommon, may require 
immediate attention. Varicose veins located near bony prominences are more 
prone to hemorrhage, and bleeding is usually due to minor trauma. Hemorrhage, 
in most cases, can be controlled with direct pressure and elevation of the leg. When 
these measures fail to sufficiently control bleeding, injections with lidocaine with 
epinephrine, suturing, and topical hemostatic agents may be helpful. Though no 
formal studies have specifically looked at topical agents to help with varicose bleed-
ing, anecdotally, the use of topical thrombin, TXA, and absorbable gelatin foam 
may stop bleeding or control it until more definitive surgical interventions can be 
performed [56, 57].
5.3 Bleeding arteriovenous fistula
Arteriovenous (AV) fistula is the vascular access preferred for long-term hemo-
dialysis in patients with end-stage renal disease. Hemodialysis accesses are subject 
to complications such as clotting, stenosis, infection, and hemorrhage. Access 
complications are common among hemodialysis patients, but they are usually not 
life-threatening. Fatal vascular access hemorrhage is very rare with an incidence of 
only 0.4%, but when these patients present to the emergency department, various 
measures can be employed in order to control the bleeding until definitive measures 
can be taken, usually by a vascular surgeon. Most of the literature regarding fistula 
bleeding is related to intraoperative bleeding which can be controlled with suturing, 
topical thrombin, and cellulose gelatin foam. Extrapolating this data, one could 
conclude that emergency department management of AV fistula bleeding should 
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involve direct pressure to the site of bleeding with the aid of topical thrombin 
products and gelatin foam products. Definitive treatment usually will involve suture 
repair done by a vascular surgeon either in the emergency department or operating 
room [58].
5.4 Bleeding from dental extraction
Post-extraction bleeding is a recognized, frequently encountered complication 
in dental practices. It is defined as bleeding that continues beyond 8–12 hours after 
dental extraction. The incidence of post-extraction bleeding varies from 0 to 26%. 
If post-extraction bleeding is not managed, complications can range from soft tissue 
hematomas to severe blood loss. Local causes of bleeding include soft tissue and 
bone bleeding. Systemic causes include platelet problems, coagulation disorders, or 
excessive fibrinolysis. There is a wide array of techniques suggested for the treat-
ment of post-extraction bleeding, which include interventions aimed at both local 
and systemic causes. Many of these patients will present to the emergency depart-
ment with their bleeding complications. In addition to treating systemic causes, 
many techniques can be employed to control the local etiologies of the bleeding. 
Surgical interventions mainly involve suturing of the site. In addition, nonsurgical 
hemostatic measures can be employed as well as combination therapy with surgical 
and nonsurgical techniques. Nonsurgical measures commonly include hemostatic 
agents such as oxidized cellulose, gel foam, thrombin, collagen fleeces, cyanoac-
rylate glue, acrylic or surgical splints, and local antifibrinolytic solutions, such as 
tranexamic acid mouthwash [59].
5.5 Epistaxis
Epistaxis is a common problem encountered in the emergency department. It 
occurs in up to 60% of the general population; however, 10% or fewer seek medical 
attention. Epistaxis can be classified as anterior with the common source of bleed-
ing being Kiesselbach’s plexus or posterior with the source being the sphenopalatine 
artery. Initial treatment at home or in the emergency department include conser-
vative measures such as blowing the nose to remove clots, using vasoconstrictive 
sprays such as oxymetazoline, applying steady pressure for 10 minutes, placing cold 
compresses on the bridge of the nose, placing a cotton pledget in the nostril, and 
having the patient bend forward so as not to accumulate blood in the oropharynx. 
When these measures fail, more invasive measures can be used such as cautery, 
nasal packing with tampons, gauze, or balloon catheters. There has recently been 
more literature regarding the use of thrombogenic foams and gels as well as the use 
of TXA as an adjunct to these measures. Fibrin glue is a safe and effective addition 
and has been shown to be as effective as cautery and packing [60]. Thrombin gel, 
such as Floseal, was associated with an absolute 26% lower rebleeding rate com-
pared with nasal packing and was easier to insert and judged more satisfactory by 
both providers and patients in a randomized trial of 70 patients with acute anterior 
nosebleeds [14]. In another prospective study, FloSeal® effectively controlled 
posterior bleeds in 8 of 10 patients whose initial packing failed [61]. Surgicel® and 
Gelfoam® are common conformable hemostatic materials and have been described 
in reviews or small case series as useful in nasal bleeding refractory to cautery [62]. 
These materials can be trimmed to an appropriate size and then applied directly 
to the bleeding source. Tranexamic acid has been studied for epistaxis and has 
shown some benefit in both short-term cessation of bleeding and decreasing rates 
of rebleeding. There was also a trend towards improved control of bleeding when 
directly compared to nasal packing alone. The delivery of TXA can be done by using 
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an atomizer and/or saturating nasal tampons with topical application of 500 mg of 
the IV formulation (TXA 100 mg/ml). Care must be taken in patients with higher 
risk of systemic thrombosis as systemic absorption may be variable when TXA is 
applied to the nasal mucosa [63].
6. Conclusion
A number of products are available to assist in topical hemostasis. The choice of 
which product to use is based partly on availability as well as the particular applica-
tion. Similarly, there are multiple tissue adhesives available on the market, but the 
provider will likely be limited to one or two different products.
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